Literature DB >> 15607900

Paraoxonase-1 does not reduce or modify oxidation of phospholipids by peroxynitrite.

Philip W Connelly1, Dragomir Draganov, Graham F Maguire.   

Abstract

Serum paraoxonase (PON1) is a high-density lipoprotein (HDL)-associated esterase/lactonase implicated to play a role in protection against atherosclerosis. However, the exact mechanism(s) and substrates for PON1 are still uncertain. In this article, we review some of the evidence for PON1's antioxidant activity, as well as our efforts to identify the actual substrates and products for this activity. We originally reported that PON1 had phospholipase activity toward oxidized phosphatidylcholine (J. Biol. Chem. 276:24473-24481; 2001). Subsequently, Marathe et al. (J. Biol. Chem. 278:3937-3947; 2003) reported that this activity was due to a contaminating lipase. However, that article did not replicate the conditions used in our previous study. To address this controversy, we purified serum PON1 by a modified method that separates the paraoxonase activity from an activity detectable as platelet-activating factor acetyl hydrolase (PAF-AH) (Teiber et al., J. Lipid. Res. 2004; Epub ahead of print, PMID 15342686) and reexamined the oxidation of phosphatidylcholine by peroxynitrite using 3-morpholinosydnonimine as a peroxynitrite generator and apolipoprotein AI-phosphatidylcholine- PON1 complexes. The phosphatidylcholines were studied by electrospray ionization tandem mass spectrometry. PON1 preparations free of PAF-AH activity showed no phospholipase activity when reconstituted into apolipoprotein AI-phosphatidylcholine complexes. We conclude that PON1 does not affect the accumulation of phosphatidylcholine oxidation products. Further, we have no evidence that PON1 has an intrinsic phospholipase A2 activity toward oxidized phospholipids.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15607900     DOI: 10.1016/j.freeradbiomed.2004.10.010

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  9 in total

Review 1.  Anti-oxidant properties of high-density lipoprotein and atherosclerosis.

Authors:  Eugene A Podrez
Journal:  Clin Exp Pharmacol Physiol       Date:  2010-03-30       Impact factor: 2.557

2.  Differential effect of lysophospholipids on activities of human plasma paraoxonase1, either soluble or lipid-bound.

Authors:  Cheon Ho Park; Su Duy Nguyen; Mee Ree Kim; Tae-Sook Jeong; Dai-Eun Sok
Journal:  Lipids       Date:  2006-04       Impact factor: 1.880

Review 3.  The human paraoxonase gene cluster as a target in the treatment of atherosclerosis.

Authors:  Zhi-Gang She; Hou-Zao Chen; Yunfei Yan; Hongliang Li; De-Pei Liu
Journal:  Antioxid Redox Signal       Date:  2011-10-18       Impact factor: 8.401

4.  HDL and Oxidation.

Authors:  Qi Zhang; Zongzhe Jiang; Yong Xu
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  HDL lipid composition is profoundly altered in patients with type 2 diabetes and atherosclerotic vascular disease.

Authors:  C Morgantini; D Meriwether; S Baldi; E Venturi; S Pinnola; A C Wagner; A M Fogelman; E Ferrannini; A Natali; S T Reddy
Journal:  Nutr Metab Cardiovasc Dis       Date:  2014-01-22       Impact factor: 4.222

6.  Paraoxonase 1, B Vitamins Supplementation, and Mild Cognitive Impairment.

Authors:  Joanna Perła-Kaján; Olga Włoczkowska; Anetta Zioła-Frankowska; Marcin Frankowski; A David Smith; Celeste A de Jager; Helga Refsum; Hieronim Jakubowski
Journal:  J Alzheimers Dis       Date:  2021       Impact factor: 4.472

Review 7.  Protein modification by aldehydophospholipids and its functional consequences.

Authors:  Ute Stemmer; Albin Hermetter
Journal:  Biochim Biophys Acta       Date:  2012-03-16

Review 8.  Antioxidative activity of high-density lipoprotein (HDL): Mechanistic insights into potential clinical benefit.

Authors:  Fernando Brites; Maximiliano Martin; Isabelle Guillas; Anatol Kontush
Journal:  BBA Clin       Date:  2017-08-19

Review 9.  HDL Composition, Heart Failure, and Its Comorbidities.

Authors:  Ahmed Diab; Carla Valenzuela Ripoll; Zhen Guo; Ali Javaheri
Journal:  Front Cardiovasc Med       Date:  2022-03-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.